U.S. FDA approves Cangene's anti-hepatitis B product
01-Feb-2006
Cangene manufactures HepaGam B(TM) in its Winnipeg facility using a process similar to that of WinRho(R) SDF and Vaccinia immune globulin, the Company's earlier FDA-approved drugs. The Company anticipates that the drug will be distributed in the U.S. by Apotex Corp., a member of the Apotex Group, Cangene's majority shareholder. The companies expect to launch the product within the next few months.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.